Replies to post #205318 on Biotech Values

[DewDiligence]

BMY—I would argue that a fairly high probability of Opdivo + Yervoy failure in NSCLC is already baked into the valuation.

p.s. Opdivo + Yervoy is also being tested in SCLC, which represents 10-15% of lung cancers.